Idorsia Aktie

1,73 EUR -0,02 EUR -1,09 %

13:40:04

STU

1,69 CHF +0,04 CHF +2,55 %

14:07:12

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.359,40 Mio. EUR

Div. Rendite0,00%

WKNA2DTEB

ISINCH0363463438

SymbolIDRSF

Idorsia Aktien News

Sortieren:Datum Meistgelesen

28.05.25GlobeNewswireShareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025

21.05.25GlobeNewswireNew funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability

02.05.25GlobeNewswireIdorsia issues invitation to the 2025 Annual General Meeting of Shareholders

WerbungIdorsia-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

30.04.25GlobeNewswireIdorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset

29.04.25GlobeNewswireNew data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine

16.04.25GlobeNewswireHigher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond

09.04.25GlobeNewswireThe effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

09.04.25GlobeNewswireUS FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement

27.03.25GlobeNewswireIdorsia publishes its Annual Report 2024

17.03.25GlobeNewswireUS FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients

14.03.25GlobeNewswireIdorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia

04.03.25GlobeNewswireIdorsia announces financial results for 2024

27.02.25GlobeNewswireInvitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call

26.02.25GlobeNewswireIdorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations

26.02.25GlobeNewswireIdorsia and Viatris update their collaboration for selatogrel and cenerimod

26.02.25GlobeNewswireIdorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties

25.02.25GlobeNewswireBondholders approve amended terms of the 2025 convertible bonds

12.02.25GlobeNewswireIdorsia publishes the resolutions for the upcoming bondholder meeting

15.01.25GlobeNewswireIdorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders

14.01.25GlobeNewswireIdorsia publishes an invitation to a bondholder meeting

13.01.25GlobeNewswireIdorsia to call for a bondholder meeting

20.12.24GlobeNewswireIdorsia provides update on the exclusive negotiations for the global rights to aprocitentan

27.11.24GlobeNewswireIdorsia enters into exclusive negotiations for global rights to aprocitentan

11.11.24GlobeNewswireIdorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions

29.10.24GlobeNewswireIdorsia announces financial results for the first nine months of 2024

16.10.24GlobeNewswireNew data on aprocitentan to be presented at the ASN Kidney Week 2024

17.09.24GlobeNewswireIdorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024

05.09.24GlobeNewswireNew data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024

02.09.24GlobeNewswireAmended terms of Idorsia’s 2024 convertible bonds become effective

25.07.24GlobeNewswireIdorsia announces financial results for the first half 2024

18.07.24GlobeNewswireInvitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call

01.07.24GlobeNewswireIdorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension

28.06.24GlobeNewswireHigher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds

25.06.24GlobeNewswireHigher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds

21.06.24GlobeNewswireIdorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category

13.06.24GlobeNewswireIdorsia holds its Annual General Meeting of Shareholders

03.06.24GlobeNewswireNew data with daridorexant to be presented at SLEEP 2024

31.05.24GlobeNewswireData from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

23.05.24GlobeNewswireIdorsia issues invitation to the 2024 Annual General Meeting of Shareholders

21.05.24GlobeNewswireIdorsia announces changes to Idorsia Executive Committee and Board of Directors

Idorsia News

Idorsia News: auf dieser Seite finden Sie alle Idorsia News und Nachrichten zur Idorsia Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Idorsia News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Idorsia News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.